共查询到20条相似文献,搜索用时 62 毫秒
1.
2.
目的:观察新型冠状病毒肺炎(COVID-19,简称新冠肺炎)相关心肌损伤的特点,分析其危险因素及预后.方法:回顾性分析2019年12月25日-2020年2月18日江汉大学附属医院收治的785例新冠肺炎患者的临床资料,按超敏肌钙蛋白(cTNI/cTNT)升高是否超过第99百分位上限(URL)分为心肌损伤组和非心肌损伤组,... 相似文献
3.
金荣华 《首都医科大学学报》2020,41(2):149-154
2019年新型冠状病毒肺炎肆虐全国,严重威胁我国人民生命健康。作为一种新发/突发传染病,其病原学、流行病学、发病机制、临床特点、治疗方案和预防策略均在探索和研究中,本文通过对最新的文献解读,帮助临床医师更好地了解这一新发/突发传染病。 相似文献
4.
新型冠状病毒肺炎(corona virus disease 2019,COVID-19)自暴发以来造成全球大流行,给人类健康和全球经济带来了极大的影响.现有研究表明:COVID-19与心血管疾病的发展密不可分.更值得注意的是,合并心血管疾病的COVID-19患者病死率明显增加.本文旨在从COVID-19的临床症状、CO... 相似文献
5.
6.
7.
新型冠状病毒肺炎是由冠状病毒2型(SARS-CoV-2)引起的一种严重急性呼吸综合征.由于SARS-CoV-2的迅速传播正在持续危及全人类健康和世界经济,迫切需要制定遏制病毒传播的策略.疫苗接种是预防其快速传播的有效方法之一.本文就新型冠状病毒肺炎疫苗的研究进展、安全性、挑战与展望进行综述. 相似文献
8.
9.
目的:分析新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)患者肝功能损伤的特征。方法:回顾性分析2020年1月21日至2月20日重庆医科大学附属永川医院收治确诊的90例COVID-19患者临床资料,总结分析COVID-19发生肝功能损伤的原因及特征。结果:90例确诊患者共33例出现肝功能损伤,肝功能损伤率为36.7%,发生肝功能损伤的平均时间为(9.0±6.1)d;轻症组肝功能损伤率为32.5%,重症组肝功能损伤率为61.5%,差异具有统计学意义(P<0.05);轻症组体质指数(body mass index,BMI)为(24.3±2.3)kg/m2,重症组BMI为(22.7±3.6)kg/m2,差异具有统计学意义(P<0.05);肝功能损伤与性别、年龄、肝脏基础疾病无统计学差异(P>0.05)。结论:出现肝功能损伤以轻度损伤为主,与原发疾病、疾病严重程度、BMI有关,药物、肝脏基础疾病可能起了一定促进作用。随着原发病好转,肝损伤逐渐好转,预后较好。 相似文献
10.
2019年底由新型冠状病毒(SARS-COV-2)感染导致的新型冠状病毒肺炎(COVID-19)疫情已被世界卫生组织定义为全球大流行.随着相关研究的不断深入,发现除呼吸系统病变外,肾脏损伤是COVID-19的主要并发症之一,危重症患者中急性肾损伤的发生率较高且影响患者预后.文章结合最新研究对COVID-19肾脏损害的可... 相似文献
11.
12.
目的 报道广西首次发生的一起家庭聚集性新型冠状病毒肺炎疫情的流行病学特征和临床特点。方法 详细收集和分析一家庭10名成员中7名感染新型冠状病毒的流行病学、临床表现、实验室检查和放射影像学。结果 2020年1月18日居住在武汉的6名成员从武汉来到南宁,并与居住在南宁的4名成员一起生活。6名居住在武汉的成员有4名感染新型冠状病毒。4名近期没有去过武汉居住在南宁的成员有3名感染新型冠状病毒。7名患者年龄中位数37岁,其中包括一名11岁儿童。从出现症状到确诊的时间为1~7 d。临床症状包括干咳(42.85%)、肌痛(42.85%)、发热(28.57%)、疲乏(28.57%)、咽痛(14.28%)、头晕(14.28%)、鼻塞(14.28%),没有患者出现呼吸困难。炎症标志物C反应蛋白和降钙素原正常。淋巴细胞计数减少3例(42.85%),CD4+T淋巴细胞降低1例(16.67%)。5名患者肺部出现磨玻璃样病灶。结论 新型冠状病毒肺炎可在家庭成员之间互相传播。我们需要重视家庭人与人之间的传染,加强家庭聚集性病例的管理。 相似文献
13.
14.
Rong Wang Cai-Hong Wang Xiao-Wen Yao Yu-Xia Zhou Xiao-Hui Yu Jiu-Cong Zhang 《海南医学院学报》2021,27(24):1-5
Novel coronavirus pneumonia(COVID-19) is a highly pathogenic infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Until now, the new crown pneumonia has caused hundreds of millions of people worldwide to be infected. Novel coronavirus pneumonia is still a high level of variation. Due to the high variability of COVID-19, there are already a large number of COVID-19 variant strains that are still at a high level of infection worldwide. Recently, WHO (WHO) released a new variant, "Mu" (μ, B.1.621) may be a high vaccine tolerance. This paper reviews the latest research progress of "Mu" virus strain in detail. 相似文献
15.
《Medical Journal Armed Forces India》2023,79(3):253-261
Since the beginning of Corona Virus Disease (COVID) pandemic, there has been lack of clarity about the management protocols in spite of frequently updated national and international guidelines. Irrational use of unproven therapies has not been helpful in improving treatment outcomes. Early use of high-dose steroids or late use of antiviral medicines might have caused more harm than the benefit. There is also lot of fear about post-COVID fibrosis leading to extended use of steroids and antifibrotics. We reviewed the available COVID guidelines and treatment protocols in the light of scientific evidence generated over last 2 years by a systematic literature search using various databases (PubMed, Google Scholar, MEDLINE, UpToDate, Embase, and Web of Science). This article presents a comprehensive approach to the diagnosis, appropriate investigations, their interpretations, and use of specific therapies according to the stage of disease. 相似文献
16.
Grace Oscullo Jose Daniel Gmez-Olivas Thais Beauperthuy Amina Bekki Alberto Garcia-Ortega Maria Gabriella Matera Mario Cazzola Miguel Angel Martinez-Garcia 《中华医学杂志(英文版)》2022,135(20):2398
Bronchiectasis (BE) has been linked to past viral infections such as influenza, measles, or adenovirus. Two years ago, a new pandemic viral infection severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) broke out and it still persists today, and a significant proportion of surviving patients have radiological and clinical sequelae, including BE. Our aim was to thoroughly review the information available in the literature on the bidirectional relationship between SARS-CoV-2 infection and the development of BE, as well as the impact of this infection on patients already suffering from BE. Available information indicates that only a small percentage of patients in the acute phase of coronavirus disease 2019 (COVID-19) pneumonia develop BE, although the latter is recognized as one of the radiological sequelae of COVID-19 pneumonia, especially when it is caused by traction. The severity of the initial pneumonia is the main risk factor for the development of future BE, but during the COVID-19 pandemic, exacerbations in BE patients were reduced by approximately 50%. Finally, the impact of BE on the prognosis of patients with COVID-19 pneumonia is not yet known. 相似文献
17.
18.
尽管SARS-CoV-2暴露剂量和暴露者机体抵抗力都是受多种因素影响难以确定的变量,但COVID-19的发生是SARS-CoV-2暴露剂量与暴露者机体抵抗力相互作用的结果。本文通过比较中国湖北内外发病情形、湖北之外其他省市不同日期COVID-19发病的潜伏期、以及散发病例与聚集性发病情形,发现SARS-CoV-2感染率高低与疫情时程及潜伏期均相关,显示SARS-CoV-2暴露剂量与是否发病、以及发病后的严重程度均可能具有相关性。从而提示COVID-19的治疗,需要对潜伏期偏短的患者提防其重症化和死亡风险。 相似文献
19.
Jason Pik Eu Chang Yu Jun Wong Wei Lyn Yang Kieron Boon Leng Lim Poh Seng Tan Gim Hin Ho Benjamin Cherng Hann Yip James Weiquan Li Chern Hao Chong David Eng Hui Ong Tju Siang Chua Charles Kien Fong Vu Kok Ann Gwee Tiing Leong Ang Chee Kiat Tan 《Singapore medical journal》2020,61(12):619
In this paper, we aim to provide professional guidance to clinicians who are managing patients with chronic liver disease during the current coronavirus disease 2019 (COVID-19) pandemic in Singapore. We reviewed and summarised the available relevant published data on liver disease in COVID-19 and the advisory statements that were issued by major professional bodies, such as the American Association for the Study of Liver Diseases and European Association for the Study of the Liver, contextualising the recommendations to our local situation. 相似文献
20.
从新型冠状病毒肺炎(COVID-19)疫情初始至今,COVID-19的病原体新型冠状病毒(SARS-CoV-2)不断进化和变异,产生传播力和毒力变化的变异株,如Alpha(B.1.1.7)、Beta(B.1.351)、Gamma(P.1)、Delta(B.1.617.2)以及Omicron(B.1.1.529)变异株。深入研究不同变异株感染所致的COVID-19潜伏期有助于追溯传染源,确定密切接触者的留验、检疫和医学观察期限,为及时调整COVID-19疫情防控措施提供依据。本文主要综述了国内外感染SARS-CoV-2野生株和不同变异株的COVID-19潜伏期的相关研究,研究发现,感染SARS-CoV-2野生株的潜伏期在4~8 d,中位潜伏期约为5.5 d。感染Beta、Gamma变异株的潜伏期与野生株基本类似,约为5 d。感染Alpha、Delta和Omicron变异株的潜伏期则低于其他毒株,分别为4 d、4 d和3 d。 相似文献